ArticleBJS open2026
Drain management after pancreatoduodenectomy: risk-stratified dynamic algorithm.
Article in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe ability of drain fluid amylase (DFA) to predict pancreatic fistula (POPF) and safely guide early drain removal is unknown in high-risk pancreatoduodenectomy (HR-PD). The aim of this analysis was to develop a new risk-based algorithm for drain management after pancreatoduodenectomy.
methodsAll consecutive patients undergoing pancreatoduodenectomy (2019-2024) at two institutions were included. During surgery, patients were stratified into HR-PD, defined according to the International Study Group on Pancreatic Surgery score (soft gland and duct ≤ 3 mm), and non-HR-PD. Postoperative predictors (DFA, serum amylase/lipase, C-reactive protein) were retrieved on postoperative days (PODs) 1 to 5 and correlated to POPF development using a risk-based approach. Results were validated in a retrospective cohort (2015-2019) of pancreatoduodenectomies performed at the same institutions.
resultsOut of 825 screened patients, 788 were included. HR-PD (251, 32%) had higher POPF rates (50% versus 9%; P < 0.001) and worse outcomes. In HR-PD, DFA had a lower area under the curve for POPF for POD 1 (0.73 versus 0.85; P = 0.003) and POD 3 (0.74 versus 0.88; P = 0.002) compared with non-HR-PD, but similar for POD 5 (0.83 versus 0.86; P = 0.535), whereas serum amylase/lipase maintained a low area under the curve for POPF compared with non-HR-PD. The optimal criteria for POD 3 drain removal in non-HR-PD were POD 1 DFA < 200 UI/l, POD 3 DFA < 150 UI/l, and absence of elevated serum amylase/lipase on POD 1 (Youden's index 0.674). In HR-PD, the criteria for POD 5 drain removal were POD 5 DFA < 150 UI/l and POD 5 C-reactive protein < 150 mg/ml (Youden's index 0.593).
conclusionIn patients with an intrinsic higher risk of POPF, early predictors are less reliable, and drain management protocols should be tailored. In non-HR-PD, an early removal policy can be recommended based on DFA and serum amylase/lipase. In HR-PD, drain removal may be safely deferred until POD 5 according to DFA and C-reactive protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.